Shanghai pharma company wins put-option dispute

A Shanghai-based pharmaceutical company has sought to enforce an ICDR award worth over US$40 million against the founder of a New Jersey-based medical practices network who has been implicated in a bank fraud conspiracy.

Unlock unlimited access to all Global Arbitration Review content